Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political resistance continue to hinder progress, experts emphasized at IAS 2025.
Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
There is currently a movement to “de-medicalize" PrEP by pushing for more availability at more casual settings than government clinics, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.
The most common HIV antibody blood test is called an “A-0” test, which is available for approximately 70 cents in many low- and middle-income countries, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.
Here’s what you missed this week on Managed Healthcare Executive.
In this part two interview of a three-part video series, Hari Prasad, CEO of Yosi Health, said in an interview with MHE that AI can reduce administrative delays in prior authorization, but it must be paired with oversight to ensure patient safety.
A new survey by eHealth and Retirable finds that 80% of Americans worry Medicare and Social Security won’t be available when they need them, amid projections that both trust funds could be depleted by 2034.
A new study found that commercial insurers pay hospitals more than twice what Medicare does, with prices varying depending on local market factors such as hospital concentration and insurer competition.
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, according to the Merck news release.
During a KFF media call, experts raised alarms that new Medicaid rules in the federal budget law could lead to coverage losses, higher costs and added pressure on states and hospitals.
Period-induced alcohol cravings and societal changes are contributing to a rising trend in women drinking, according to new research from Sarah McKetta, M.D., Ph.D., assistant professor, Mailman School of Public Health, Columbia University and Layne Robinson, clinical psychology doctoral student and graduate research assistant in the RISK Laboratory, University of Kentucky.
Michael Abrams, M.A., managing partner at Numerof & Associates, warned that without clear eligibility rules, the new $50 billion rural hospital relief fund could end up helping the wrong providers instead of the rural hospitals most in need.
Managed Healthcare Executive spoke with Michael Abrams, M.A., managing partner at Numerof & Associates, to discuss the newly passed $50 billion rural hospital relief fund and what it could mean for rural health systems. In a conversation that took place just before the legislation passed in the Senate on July 1, Abrams expressed cautious support for the fund while warning that without proper structure, it could fall short of meaningful change.
In an interview with Managed Healthcare Executive ahead of the Senate and House vote and under President Trump's official seal of approval on July 4, Michael Abrams, M.A., warned that without clear eligibility rules, the newly approved $50 billion rural hospital relief fund could be exploited by non-rural providers and fail to support the facilities it was meant to save.
For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise steadily over 10 years despite being prescribed medications intended to protect against it, researchers reported in a retrospective study.
Menopause therapy coverage varies by insurance type and is dependent on FDA approval status, clinical guidelines and prior authorizations, all of which are best navigated with the help of a managed care pharmacy expert, according to Susan Cantrell, CEO, Academy of Managed Care Pharmacy.
The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.
Orsini will be the specialty pharmacy partner for Ekterly.
Here’s what you missed this week on Managed Healthcare Executive.
In a conversation with Managed Healthcare Executive, Michael Abrams, M.A., managing partner at Numerof & Associates, painted a picture of what’s at stake.
Care gaps in women’s health are closing, thanks to increased cultural awareness of gendered healthcare disparities, according to Susan Cantrell, CEO of the Academy of Managed Care Pharmacy.
Sonali Kulkarni, M.D., M.P.H., Medical Director in the Division of HIV and STD Programs at the Los Angeles County Department of Public Health, recently sat down with Managed Healthcare Executive to explain the barriers within the traditional healthcare system for homeless HIV patients and the importance of mobile care clinics.
The financial balancing act between providers, government programs and commercial insurers, according to Christoph Dankert, chief network officer of Carrum Health.
Patients addicted to opioids receive less mental health care if they are only covered by public insurance, compared with patients receiving care through alternate funding, according to a recent study published in Addiction Science & Clinical Practice.
Here’s what you missed this week on Managed Healthcare Executive.
Employers are key to transforming healthcare by creating competitive, cost-effective networks independent of federal policy changes, according to Christoph Dankert, chief network officer of Carrum Health.
As sweeping policy shifts and rising restrictions threaten LGBTQ+ health access, providers, payers and employers reflect on what’s at stake in Pride Month's end—and what it will take to protect affirming equitable care for the future.
Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.
Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their prescription filled through CenterWell Pharmacy, now associated with Novo Nordisk and WeightWatchers.
